Many patients are, perhaps inappropriately, denied the benefits of autologous blood transfusion, because they are thought to be too ill to donate blood safely. The safety and efficacy of autologous blood donation by selected patients with end‐stage heart or lung disease who are awaiting organ transplantation were studied to determine if even these critically ill patients could be suitable candidates for autologous blood donation. Seventy‐two adults awaiting heart or lung transplantation were evaluated for autologous blood donation in a hospital‐based blood collection facility. Phlebotomy was performed if the patient met the required medical eligibility protocol, and if he or she consented to participate. Units of blood were separated into packed red cells and plasma and stored in a frozen state. Of 48 heart transplant candidates, 31 (65%) were each able to donate 1 to 8 units of blood. The median number of exposures to allogeneic components was 1 for patients who donated and 7 for nondonors (p = 0.0141). Among patients who donated, 54 percent required allogeneic components, as compared to 88 percent of nondonors (p = 0.0968). Of 24 lung transplant candidates, 15 (63%) made 1 to 6 donations each. The median number of exposures to allogeneic components was 0 for donors and 2 for nondonors (p = 0.1871), but only 45 percent of donors required allogeneic components, as compared to 100 percent of nondonors (p = 0.0418). No serious complications during or following phlebotomy were observed. It is concluded that autologous blood donation by patients with end‐stage heart or lung disease may be safe. However, to delineate fully which patients can participate, additional stuchs of safety are required, including more objective measurements of postdonation hemodynamics in these and other “high‐risk' patients. But, because avoidance of exposure to allogeneic components or significant reduction in total exposures has been possible for many patients, it is imperative that further studies of safety and effectiveness be undertaken. The out‐ come of this current study sug ests that the benefits of preoperative autologous blood donation can be extended safely to man patients previously considered too sick to participate.
[1]
J. Matloff,et al.
Autologous Blood Transfusion in Coronary Artery Bypass Surgery
,
2003,
Transfusion.
[2]
B. Spiess,et al.
Autologous blood donation: hemodynamics in a high‐risk patient population
,
1992,
Transfusion.
[3]
R. Sacher,et al.
Preoperative autologous blood donations by high‐risk patients
,
1992,
Transfusion.
[4]
E. Cameron,et al.
Coronary artery bypass surgery.
,
1990,
BMJ.
[5]
R. Thurer,et al.
Autologous blood donations prior to elective cardiac surgery. Safety and effect on subsequent blood use.
,
1989,
JAMA.
[6]
R. Mammana,et al.
Autologous platelet-rich plasma in cardiac surgery: effect on intraoperative and postoperative transfusion requirements.
,
1988,
The Annals of thoracic surgery.
[7]
R. Strauss,et al.
Predeposited autologous blood for elective surgery. A national multicenter study.
,
1987,
The New England journal of medicine.
[8]
D. Surgenor.
The patient's blood is the safest blood.
,
1987,
The New England journal of medicine.
[9]
E. E. Glazer,et al.
Utilization and effectiveness of a hospital autologous preoperative blood donor program
,
1986,
Transfusion.
[10]
L. Cuello,et al.
Autologous blood transfusion in thoracic and cardiovascular surgery.
,
1967,
Surgery.
[11]
R. M. Harvey,et al.
Nomenclature and criteria for diagnosis of diseases of the heart and great vessels
,
1973
.